Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
4DMedical Ltd ( (AU:4DX) ) has shared an update.
4DMedical Limited has issued 20,806,185 fully paid ordinary shares without a disclosure document, relying on provisions of the Corporations Act that allow such an issue by a compliant disclosing entity. The company confirmed it has met its continuous disclosure and financial reporting obligations and stated there is no excluded information that must be disclosed, signalling that the new shares can trade freely on the market and providing assurance to investors about the company’s regulatory compliance and transparency around this capital issuance.
The most recent analyst rating on (AU:4DX) stock is a Hold with a A$4.50 price target. To see the full list of analyst forecasts on 4DMedical Ltd stock, see the AU:4DX Stock Forecast page.
More about 4DMedical Ltd
4DMedical Limited (ASX:4DX) is a global medical technology company focused on revolutionising respiratory care through advanced imaging and artificial intelligence. Its patented XV Technology transforms standard medical scans into detailed functional lung insights, underpinning a growing software portfolio that includes FDA-cleared XV Lung Ventilation Analysis Software (XV LVAS), CT LVAS and the CT:VQ solution, all delivered via a Software-as-a-Service model that integrates with existing hospital systems to enhance diagnosis, monitoring and personalisation of care for patients with lung disease worldwide.
Average Trading Volume: 5,078,969
Technical Sentiment Signal: Buy
Current Market Cap: A$2.61B
For a thorough assessment of 4DX stock, go to TipRanks’ Stock Analysis page.